Figure 2 | Cell Death & Disease

Figure 2

From: The combination of the prodrugs perforin-CEBPD and perforin-granzyme B efficiently enhances the activation of caspase signaling and kills prostate cancer

Figure 2

The abundance of CEBPD is negatively associated with the levels of E2F1, EZH2 and SUZ12 in PrCa specimens. (a) By analyzing a published transcriptome data set of metastatic versus localized PrCa samples, E2F1, EZH2 and SUZ12 are significantly upregulated, whereas CEBPD is downregulated in metastatic lesions. Notably, the level of CEBPD transcript is negatively associated with the levels of E2F1, EZH and SUZ12. Primary localized PrCa (blue lines) and metastatic PrCa (brown lines) tissue specimens are indicated on top of the heat map and the relative expression levels of the upregulated and downregulated genes were expressed in the brightness of the red and green colors, respectively, with those genes with unaltered in mRNA expression being colored black. An immunohistochemical study (b) with the statistical analysis (c) of E2F1, EZH2, SUZ12 and CEBPD in representative non-neoplastic prostate tissue (left panel), localized (middle) and metastatic prostate carcinomas shows stepwise increases in E2F1, EZH2 and SUZ12 levels as well as a stepwise downregulation of CEBPD. Furthermore, the positive associations between E2F1, EZH2 and SUZ12 expression levels and their negative association with the CEBPD expression level are also illustrated (d)

Back to article page